Literature DB >> 34955416

Radiotherapy of anal canal cancer.

D Peiffert1, F Huguet2, V Vendrely3, L Moureau-Zabotto4, E Rivin Del Campo2, G Créhange5, A-S Dietmann6, A Moignier7.   

Abstract

We present the update of the recommendations of the French society for radiation oncology on external radiotherapy and brachytherapy of anal canal carcinoma. The following guidelines are presented: indications, treatment procedure, as well as dose and dose-constraints objectives, immediate postoperative management, post-treatment evaluation, and long-term follow-up.
Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anal canal carcinoma; Brachytherapy; Cancers du canal anal; Curiethérapie; French society for radiation oncology; Guidelines; Radiotherapy; Radiothérapie; Recommandations; Recommendations; Société française de radiothérapie oncologique

Mesh：

Year:  2021        PMID： 34955416     DOI： 10.1016/j.canrad.2021.11.015

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN： 1278-3218            Impact factor:   1.018


  1 in total

1.  Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Authors:  Stefano Kim; Jihane Boustani; Dewi Vernerey; Véronique Vendrely; Ludovic Evesque; Eric Francois; Laurent Quero; Francois Ghiringhelli; Christelle de la Fouchardière; Laëtitia Dahan; Oliver Bouché; Benoist Chibaudel; Farid El Hajbi; Chloé Vernet; Magali Rebucci-Peixoto; Alexandra Feuersinger; Christophe Maritaz; Christophe Borg
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.